Anne Klibanski '71 named CAO of Partners HealthCare
In a message from Gary Gottlieb, M.D., President and CEO of Partners HealthCare, dated March 16, 2012:
With great pleasure, I am announcing that Partners HealthCare is naming its new Chief Academic Officer (CAO) effective April 1st. She is Anne Klibanski, M.D., Chief of Neuroendocrinology at Massachusetts General Hospital (MGH) and the Laurie Carrol Guthart Professor of Medicine at Harvard Medical School. Anne, with her extensive and collaborative career in medicine, is a highly respected leader in our research community. She will be a proactive and protective voice as we work to advance our mission in today's dynamic environment where we find unprecedented opportunity amid a time of remarkable change and challenge. In her position at MGH she leads an internationally recognized program in neuroendocrine research and clinical care and will continue to direct the Neuroendocrine Unit and Endocrine Division as well as the MGH Center for Faculty Development.
In her role as CAO, Anne will collaborate with the leadership at all of our institutions to guide our scientific and educational missions to make certain that our academic enterprise is woven into our strategy and our vision for the future. In this position, she also will assume an Academic Dean role at Harvard Medical School as well as support our plans to develop innovative and even more productive relationships with local and national scientific communities and with industry.
Her distinguished career began with her education at Barnard College, New York University School of Medicine and her internship and residency at Bellevue Hospital in New York City. Anne came to Boston to join MGH as a clinical and research fellow in endocrinology, becoming director of the Neuroendocrine Clinical Center and then founding chief of the Neuroendocrine Unit. She has been director of the Harvard Catalyst Clinical Research Center since its inception and was appointed Associate Dean of Clinical and Translational Research at Harvard Medical School (HMS). Anne has made major research contributions in the areas of pituitary tumor pathogenesis and the neuroendocrine regulation of bone metabolism. Her honors and achievements are numerous, and she is a prolific author of scores of publications in her field. She is the recipient of the Endocrine Society's Clinical Investigator Award and the William Silen Lifetime Achievement in Mentoring Award from HMS.
Anne advocates that our research, educational and clinical missions must be synchronized and unified, weaving our learning and discovery to help deliver the most advanced medicine for our patients. Translational and multi-disciplinary are not simply concepts, but a belief system for her. Anne promotes that we must cross typical boundaries to challenge ourselves so we can provide the
highest quality care to our patients and address health care's pressing issues. Anne will assume the reconstituted position of CAO, as previously held by Eugene Braunwald, M.D., and Daniel Podolsky, M.D. She succeeds Denny Ausiello, M.D. who served as Partners Chief Scientific Officer since 2008. I want to take this opportunity to extend our community's deep gratitude to Denny for his lasting leadership and exceptional accomplishments. I want to thank him for his passion and dedication that have left an indelible mark on our entire system. I also want to express my appreciation to Michael Gimbrone, M.D. Mike has represented Partners as the Academic Dean at HMS. He has led the Partners Committee on Senior Appointments (PCSA) and has been a thoughtful and diligent advocate for our faculty and our mission.
Our research and our teaching help to define us. Draped in that definition are the people of Partners HealthCare whose commitment to excellence have lifted us to be recognized as a world-renowned academic medical system. As we look to the future let us do so with a sense of responsibility to strengthen our mission and set a course for the next generation. With Anne's leadership and an enduring pledge from our entire community, we are well positioned to do so.
Gary Gottlieb, M.D.
President and CEO